Short Interest in iBio, Inc. (NYSEAMERICAN:IBIO) Expands By 26.1%

iBio, Inc. (NYSEAMERICAN:IBIO) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 255,800 shares, a growth of 26.1% from the November 30th total of 202,800 shares. Based on an average trading volume of 143,900 shares, the short-interest ratio is presently 1.8 days. Approximately 2.8% of the shares of the company are sold short.

iBio Stock Performance

Shares of iBio stock opened at $2.38 on Tuesday. The company has a quick ratio of 0.91, a current ratio of 0.91 and a debt-to-equity ratio of 0.04. iBio has a twelve month low of $1.02 and a twelve month high of $4.98.

About iBio

iBio, Inc, a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.